時間 | 主題 | ||||
---|---|---|---|---|---|
Session: Prostate Cancer |
|||||
The treatment landscape of hormone treatment in prostate cancer
講者:
陳毓騏
座長:
余燦榮, 陳彥達 |
陳毓騏 |
余燦榮, 陳彥達 |
|||
How to optimize the sequential treatment for castration resistant prostate cancer?
講者:
羅浩倫
座長:
余燦榮, 陳彥達 |
羅浩倫 |
余燦榮, 陳彥達 |
|||
Retzius sparing robotic radical prostatectomy
講者:
林威宇
座長:
沈坤宏, 童敏哲 |
林威宇 |
沈坤宏, 童敏哲 |
|||
Prophylactic pelvis lymph node irradiation for prostate carcinoma
講者:
方富民
座長:
沈坤宏, 童敏哲 |
方富民 |
沈坤宏, 童敏哲 |
|||
Coffee break |
|||||
Prostate MR: Impact on clinical management
講者:
沈書慧
座長:
阮雍順, 廖俊厚 |
沈書慧 |
阮雍順, 廖俊厚 |
|||
What is the best strategy to achieve an ideal targeted biopsy and HIFU therapy for prostate cancer
講者:
陳富都
座長:
阮雍順, 廖俊厚 |
陳富都 |
阮雍順, 廖俊厚 |
|||
12-year experiences of HIFU for the treatment of prostate cancer
講者:
江博暉
座長:
阮雍順, 廖俊厚 |
江博暉 |
阮雍順, 廖俊厚 |
時間 | 主題 | ||||
---|---|---|---|---|---|
01:44 ~ 15:05 |
Discussion |
||||
Case report |
|||||
Percutaneous extraction of bladder stones in a patient with appendicovesicostomy
講者:
林致泰
座長:
李偉嘉, 陳紹寬, 廖丞晞 |
林致泰 |
李偉嘉, 陳紹寬, 廖丞晞 |
|||
08:10 ~ 08:15 |
Immunoglobulin G4 related kidney disease mimicking urothelial carcinoma, case report
講者:
葉沛豪
座長:
李偉嘉, 陳紹寬, 廖丞晞 |
葉沛豪 |
李偉嘉, 陳紹寬, 廖丞晞 |
||
08:15 ~ 08:20 |
Appendicovesicostomy as an alternative procedure for patients with advanced penile cancer
講者:
黃英哲
座長:
李偉嘉, 陳紹寬, 廖丞晞 |
黃英哲 |
李偉嘉, 陳紹寬, 廖丞晞 |
||
08:20 ~ 08:25 |
Purple renal stone
講者:
蔡牧堯
座長:
李偉嘉, 陳紹寬, 廖丞晞 |
蔡牧堯 |
李偉嘉, 陳紹寬, 廖丞晞 |
||
08:25 ~ 08:35 |
Extramedullary plasmacytoma in the testis, a case report and review of literature
講者:
李一宏
座長:
李偉嘉, 陳紹寬, 廖丞晞 |
李一宏 |
李偉嘉, 陳紹寬, 廖丞晞 |
||
Session: Urothelial Cancer |
|||||
08:35 ~ 08:45 |
Prevalence of chronic kidney disease in upper tract urothelial carcinoma endemic area and its oncological impact in real world
講者:
李懿文
座長:
鄭元佐, 康智雄 |
李懿文 |
鄭元佐, 康智雄 |
||
08:45 ~ 08:55 |
The prognostic impact of tumor location for T3N0M0 upper urinary tract urothelial carcinoma
講者:
陳子双
座長:
鄭元佐, 康智雄 |
陳子双 |
鄭元佐, 康智雄 |
||
08:55 ~ 09:05 |
MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A/B-catenin signaling
講者:
鍾悅華
座長:
鄭元佐, 康智雄 |
鍾悅華 |
鄭元佐, 康智雄 |
||
09:05 ~ 09:15 |
Discussion |
||||
09:15 ~ 09:25 |
Is lymph node dissection necessary during radical nephroureterectomy for clinically node-negative upper tract urothelial carcinoma: multi-institutional study
講者:
李香瑩
座長:
馮思中, 王賢祥 |
李香瑩 |
馮思中, 王賢祥 |
||
09:25 ~ 09:35 |
LASER fulguration for UTUC treatment
講者:
劉建良
座長:
馮思中, 王賢祥 |
劉建良 |
馮思中, 王賢祥 |
||
09:35 ~ 09:45 |
Discussion |
||||
Session: Prostate Cancer |
|||||
10:10 ~ 10:20 |
Pubovesical complex-sparing technique under hypothermia during tobotic-assisted laparoscopic Radical proststectomy
講者:
莊毓峰
座長:
歐宴泉, 陳冠州 |
莊毓峰 |
歐宴泉, 陳冠州 |
||
10:20 ~ 10:30 |
Incidental prostate cancer after robotic-assisted simple prostatectomy: a contemporary perspective from cohort study
講者:
楊哲學
座長:
歐宴泉, 陳冠州 |
楊哲學 |
歐宴泉, 陳冠州 |
||
10:30 ~ 10:40 |
Routine use of prophylactic metoclopramide after transperitoneal robotic assisted radical prostatectomy: really needed?
講者:
胡蔚祥
座長:
歐宴泉, 陳冠州 |
胡蔚祥 |
歐宴泉, 陳冠州 |
||
10:40 ~ 10:50 |
Systemic treatment for mCRPC in VGHTC
講者:
洪晟鈞
座長:
歐宴泉, 陳冠州 |
洪晟鈞 |
歐宴泉, 陳冠州 |
||
11:00 ~ 11:10 |
Consistency between biopsy and radical prostatectomy specimen gleason score - the risk of incorrect risk stratification
講者:
張顥瀚
座長:
王弘仁, 蔡芳生 |
張顥瀚 |
王弘仁, 蔡芳生 |
||
11:10 ~ 11:20 |
Preliminary experiences of sonablate HIFU in the treatment of localized prostate cancer
講者:
陳啟文
座長:
王弘仁, 蔡芳生 |
陳啟文 |
王弘仁, 蔡芳生 |
||
11:20 ~ 11:30 |
Hounsfield unit (HU) value and its correlation with indocyanine green (ICG) in patient receiving robotic-assisted adrenalectomy
講者:
劉品均
座長:
王弘仁, 蔡芳生 |
劉品均 |
王弘仁, 蔡芳生 |
||
11:30 ~ 11:40 |
Discussion |
||||
Session : Lunch Symposium |
|||||
11:55 ~ 12:25 |
Ideal reimbursed sequential therapies in advanced renal cell carcinoma management
講者:
錢祖明
座長:
王百孚, 闕士傑 |
錢祖明 |
王百孚, 闕士傑 |
||
Quantum leap for RCC treatment: from adjuvant to 1L mRCC
講者:
王賢祥
座長:
王百孚, 闕士傑 |
王賢祥 |
王百孚, 闕士傑 |
|||
12:35 ~ 12:55 |
Evolving our strategy in 1L RCC
講者:
詹鎮豪
座長:
王百孚, 闕士傑 |
詹鎮豪 |
王百孚, 闕士傑 |
||
12:55 ~ 13:05 |
Discussion |
||||
13:05 ~ 13:25 |
Real-world treatment patterns and survival outcomes in patients with advanced prostate cancer
講者:
郭哲銓
座長:
歐建慧, 溫玉清, 黃志平 |
郭哲銓 |
歐建慧, 溫玉清, 黃志平 |
||
13:25 ~ 13:45 |
Radium-223 as 1st line in symptomatic mCRPC
講者:
吳冠諭
座長:
歐建慧, 溫玉清, 黃志平 |
吳冠諭 |
歐建慧, 溫玉清, 黃志平 |
||
13:45 ~ 14:05 |
Darolutamide in nmCRPC: improving survival with quality of life
講者:
王紹全
座長:
歐建慧, 溫玉清, 黃志平 |
王紹全 |
歐建慧, 溫玉清, 黃志平 |
||
14:05 ~ 14:25 |
PROfound changes that PARP inhibitors brings to metastatic castration-resistant prostate cancer
講者:
劉惠瑛
座長:
歐建慧, 溫玉清, 黃志平 |
劉惠瑛 |
歐建慧, 溫玉清, 黃志平 |
||
A new survival standard in the first line advanced/metastatic urothelial carcinoma management
講者:
楊明昕
座長:
歐建慧, 溫玉清, 黃志平 |
楊明昕 |
歐建慧, 溫玉清, 黃志平 |